Patients with the deadliest cancer finally have something that works

The U.S. FDA approved Rasonque daraxonrasib, the first broad RAS-targeted oral drug for metastatic pancreatic cancer, nearly doubling patient survival and converting Revolution Medicines from a research-stage company to a commercial drug maker.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.